Upcoming event

Keynote-045: updated 3 years results by Andrea Necchi

October 2019

Phase 2 TROPHY-U-01 open-label study of patients receiving sacituzumab-govitecan with metastatic urothelial cancer after failure of platinum-based regimens or immunotherapy by Scott Tagawa

Ocotber 2019

Keynote-057 study: interim analysis

October 2019

NEMIO trial by Stéphane Oudard

October 2019

EAU19 congress sessions

Overview on Keynote 57: "Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG)"

February 2019

Commentary on ESOU19 webcast "Is en-bloc TUR the best staging tool?"

Prostate sparing approaches

Lessons learned from the POUT trial: adjuvant chemotherapy does improve the outcomes of patients treated with RNU for UTUC

2018 Nov 10

ESMO/EAU consensus project in muscle invasive or metastatic bladder cancer report at EMUC 2018 by Prof. Witjes

November 2018

Metastatic muscle invasive bladder cancer: When should immunotherapy be used? EMUC 2018 by Prof Bamias

2018 Nov 09

Editorial on RAZOR trial by Dr. Evanguelos Xylinas

Lancet. 2018 Jun 23